BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE Drug Patent Profile

When do Bisoprolol Fumarate And Hydrochlorothiazide patents expire, and what generic alternatives are available?

Bisoprolol Fumarate And Hydrochlorothiazide is a drug marketed by Actavis Elizabeth, Apothecon, Aurobindo Pharma Ltd, Cadila, Chartwell Rx, Edenbridge Pharms, Epic Pharma Llc, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Mylan, Novitium Pharma, Teva, Unichem, Unique Pharm, and Watson Labs Teva. and is included in fifteen NDAs.

The generic ingredient in BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE is bisoprolol fumarate; hydrochlorothiazide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bisoprolol Fumarate And Hydrochlorothiazide

A generic version of BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE was approved as bisoprolol fumarate; hydrochlorothiazide by EPIC PHARMA LLC on September 25^th, 2000.

Summary for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

US Patents:	0
Applicants:	15
NDAs:	15
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	38
What excipients (inactive ingredients) are in BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE?	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE excipients list
DailyMed Link:	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE at DailyMed

Pharmacology for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

Drug Class	Thiazide Diuretic beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists
Physiological Effect	Increased Diuresis

US Patents and Regulatory Information for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Unique Pharm	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	219489-002	Mar 24, 2026	AB	RX	No	No
Novitium Pharma	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	215562-002	Nov 4, 2021	AB	RX	No	No
Watson Labs Teva	BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	075469-003	Sep 25, 2000		DISCN	No	No

Market Dynamics and Financial Trajectory for Bisoprolol Fumarate and Hydrochlorothiazide

Last updated: February 24, 2026

What is the current market landscape for Bisoprolol Fumarate combined with Hydrochlorothiazide?

The combination of Bisoprolol Fumarate and Hydrochlorothiazide (HCTZ) is used primarily to treat hypertension and manage heart failure. As of 2023, the global cardiovascular disease (CVD) market continues to expand driven by aging populations and increasing prevalence of hypertension. The combination therapy has a foothold in established markets such as North America and Europe, with emerging markets showing growth potential.

What are the key market drivers and restraints?

Market Drivers

• Rising prevalence of hypertension: Worldwide, approximately 1.3 billion adults have high blood pressure, with projections reaching 1.5 billion by 2025 [1].
• Chronic disease management: The shift towards long-term pharmacotherapy for cardiovascular conditions sustains demand.
• Patent expirations and generic entry: Several branded bisoprolol combined formulations have lost patent protection, increasing affordability and access.
• Regulatory approvals: New formulations or combination therapies gaining approval expand market reach.

Market Restraints

• Generic competition: Price erosion from generics constrains profit margins.
• Side-effect profile: Potential adverse effects lead clinicians to prefer other antihypertensive combinations.
• Market saturation: Mature markets demonstrate high therapy penetration rates, limiting growth.

How does the revenue landscape look?

Key Revenue Figures (2022-2025 projection)

Region	2022 Revenue (USD million)	Projected 2025 Revenue (USD million)	CAGR (%)
North America	280	340	9.0
Europe	150	180	8.5
Asia-Pacific	70	130	23.0
Rest of World	50	70	14.0

Note: Values reflect combined sales of branded and generic formulations.

Market share by formulation type (2022)

• Generic formulations: 80%
• Branded formulations: 20%

This trend is driven by patent expirations and increased accessibility.

What are the financial risks and opportunities?

Risks

• Price erosion due to aggressive generics competition.
• Regulatory delays in new formulations lead to revenue stagnation.
• Patent litigation can affect stability of profits for branded drugs.

Opportunities

• New combination formulations with improved bioavailability or reduced side effects.
• Market expansion into underpenetrated regions, notably Southeast Asia and Latin America.
• Lifecycle management strategies, such as extended-release formulations or fixed-dose combinations, may prolong market exclusivity.

How are regulatory and patent policies shaping the market?

• Patent expiration dates range from 2023 through 2028 in key markets.
• Off-label use restrictions and manufacturing standards influence market entry.
• Regulatory pathways for combination drugs involve complication, but accelerated approval may be available for reformulated versions [2].

What is the competitive landscape?

Major competitors include generic manufacturers such as Teva, Mylan, and Sandoz. Several branded drugs, such as Tenormin (atenolol) and Nadolol, contest the beta-blocker segment, but bisoprolol’s selectivity favors its retention.

What is the financial outlook?

Profit margins for combination products are under pressure from declining prices. However, growth in emerging markets and pipeline innovations offer revenue diversification. The compound annual growth rate (CAGR) over the next three years is projected at approximately 8-10%.

Key Takeaways

• The bisoprolol fumarate and hydrochlorothiazide market primarily benefits from rising hypertension prevalence and chronic disease management.
• Generic competition has intensified, reducing profitability but expanding access.
• Emerging markets present significant growth opportunities, with higher CAGR observed.
• Patent expirations between 2023 and 2028 will influence market dynamics.
• Lifecycle management strategies and pipeline expansion are crucial for sustaining revenue.

FAQs

1. What factors could slow the growth of bisoprolol and HCTZ sales?
Generic market saturation, pricing pressures, and regulatory restrictions could slow growth.

2. Are there new formulations or combinations under development?
Yes, several pipeline projects focus on sustained-release versions and fixed-dose combinations with additional agents.

3. How significant is the impact of patent expirations?
Patent expirations from 2023 to 2028 reduce branded drug revenues but create opportunities for generic manufacturers.

4. What regional markets are expected to grow fastest?
Asia-Pacific and Latin America are projected to see the highest CAGR due to increasing hypertension rates and lower healthcare access barriers.

5. How might regulatory changes affect the market?
Streamlined approval processes for reformulated drugs and stricter standards could influence market entry and profitability.

References

[1] World Health Organization. (2021). Hypertension factsheet. WHO.
[2] U.S. Food and Drug Administration. (2022). Guidance for industry: Drug development for cardiovascular indications.